

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/681,788	10/08/2003	Habib Zaghouani	07316.0002.CPUS01	6701
22930 HOWREY LLP	7590 01/19/200	7	EXAMINER	
C/O IP DOCKETING DEPARTMENT 2941 FAIRVIEW PARK DR, SUITE 200 FALLS CHURCH, VA 22042-2924			EWOLDT, GERALD R	
			ART UNIT	PAPER NUMBER
	ŕ		1644	
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
30 D.	AYS	01/19/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

10 681.788

APPLICATION NO./
CONTROL NO.

FILING DATE
FIRST NAMED INVENTOR /
PATENT IN REEXAMINATION

ATTORNEY DOCKET NO.

EXAMINER

ART UNIT

PAPER

107

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 C.F.R. 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132. All sequences in the specification and figures must be identified by SEQ ID NO: and a Sequence Listing and CRF must be filed.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (571) 272-0843. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841.

Please Note: Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

G.R. EWOLDT, PH.D. PRIMARY EXAMINER

Application No.: 10(31,788

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

attention	olication clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR May 1, 1990.
	olication does not contain, as a separate part of the disclosure on paper copy, a "Sequence as required by 37 C.F.R. 1.821(c).
	of the "Sequence Listing" in computer readable form has not been submitted as required by R. 1.821(e).
☐ content	of the "Sequence Listing" in computer readable form has been submitted. However, the of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 .823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
LJ and/or u	nputer readable form that has been filed with this application has been found to be damaged unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute er readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The par	per copy of the "Sequence Listing" is not the same as the computer readable from of the noe Listing" as required by 37 C.F.R. 1.821(e).
7. Other: _	
□ .	
Applicant N	flust Provide:
An initial c	substitute computer readable form (CRF) copy of the "Sequence Listing".
	or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entro secification.
applicable	ent that the content of the paper and computer readable copies are the same and, where e, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(d).
For question	ns regarding compliance to these requirements, please contact:
For Rules Ir	nterpretation, call (703) 308-4216
For CRF Su	ubmission Help, call (703) 308-4212
For Patentle	n software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE